Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSante Pharmaceuticals has reported that Azur Pharma, the company's licensee, has initiated sales and marketing of Elestrin in the US.
Subscribe to our email newsletter
Azur will market Elestrin to estrogen prescribing physicians, comprised mostly of gynecologists. Azur recently increased its women’s health and urology sales force to 65 people to support the launch of Elestrin, said BioSante.
BioSante is entitled to receive Elestrin milestone payments of up to an aggregate of $144.5 million if certain sales-based milestones are achieved. In addition, Azur has agreed to pay to BioSante royalties on sales of Elestrin ranging from 10% to 20% depending on the annual sales level.
Elestrin (estradiol gel 0.06%) is a clean, clear, fast-drying estrogen formulation for the treatment of vasomotor symptoms associated with menopause, said BioSante. Azur licensed rights to Elestrin from BioSante in December 2008. Elestrin was approved by the FDA in December 2006 and is patented through June 2022.
Seamus Mulligan, chairman and CEO of Azur, said: “We are excited with the potential for Elestrin in the US given its low dose regimen and proven effectiveness. The product is an important addition to our women’s health product portfolio.”